Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer.
Estrogen receptor (ER) and progesterone receptor (PR) are important prognostic and predictive biomarkers in breast cancer. Positron emission tomography (PET) using ER and PR specific radioligands enables a whole-body, non-invasive assessment of receptor expression. Recent investigations of ER imaging with 18F-fluoroestradiol (18F-FES) have focused on diagnosing ER+ metastatic disease, optimizing ER-targeted drug dosage, and predicting endocrine therapy benefit. Studies of PR imaging with 18F- fluorofuranylnorprogesterone (18F-FFNP) have investigated how imaging changes in PR expression as a downstream target of ER activation may reflect an early response to ER-targeted therapy. This focused review highlights recent achievements in pre-clinical and clinical imaging of ER and PR in breast cancer.